Ocular Technologies (an Auven Therapeutics portfolio company)
Posted on: October 26, 2016
By: Kim Berlowitz
With: Comments Off on Ocular Technologies (an Auven Therapeutics portfolio company)
Exclusive financial advisor to Auven Therapeutics in the sale of Seciera, a Phase 3 clinical asset for the treatment of dry eye disease